JUL 24, 2019 10:40 PM PDT

HIV Therapeutics Places Risk of Neural Tube Defects

WRITTEN BY: Nouran Amin

In a study published in the New England Journal of Medicine, women taking an HIV therapeutic drug containing dolutegravir have a higher risk of giving birth to children with neural tube defects particularly in comparison to women taking other antiretroviral drug regimens.

Learn more on neural tube defects:

Neural tube defects consist of abnormalities in the development of the brain and spinal column. The NICHD-funded study, which began in 2014 in Botswana, was used to track birth outcomes, including neural tube defects for infants born to women taking antiretroviral therapy for an HIV infection in eight hospitals.

Upon findings, Botswana changed their treatment guidelines to recommend drug combinations containing dolutegravir for all adults, this included pregnant women. However, later preliminary studies indicated a potential risk between mothers receiving the drug and neural tube defects among their infants—this is especially true for women who received the dolutegravir treatment around the time they conceived.

During the International AIDS Society Conference, researchers reported their findings describing women that were on dolutegravir since conception. Of these women, five neural tube defects occurred out of 1,683 births (0.3%). However, women who were on the drug, efavirenz, since conception had three cases of neural tube defects out of 7,959 births (0.04%). Furthermore, women receiving another HIV treatment regimens that did not involve dolutegravir had 15 neural tube defect cases out of 14,792 births (0.1%). At the end, the findings concluded 0.2% difference in risk for infants born to women on dolutegravir drug therapy since conceiving. Although the risk is small, findings are significant.

Source: National Institute of Health

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 26, 2022
Immunology
Unraveling the Mystery of an Immune Cell Checkpoint
APR 26, 2022
Unraveling the Mystery of an Immune Cell Checkpoint
The immune system can get tired when it has to fight against a chronic infection or a disease like cancer. Exhausted T c ...
MAY 15, 2022
Drug Discovery & Development
Implanted Insulin-producing Cells for Diabetes Treatment
MAY 15, 2022
Implanted Insulin-producing Cells for Diabetes Treatment
Type 1 diabetes, which affects about 9 to 10 million people globally, occurs when the immune system incorrectly identifi ...
MAY 19, 2022
Neuroscience
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
MAY 19, 2022
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
Eating a cup of cranberries per day may improve memory, ward off dementia and reduce ‘bad’ cholesterol in th ...
JUN 02, 2022
Cancer
Call to Diversify Clinical Trials
JUN 02, 2022
Call to Diversify Clinical Trials
Clinical Trials represent an integral component of biomedical research.  These research studies utilize human subje ...
JUN 06, 2022
Drug Discovery & Development
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
JUN 06, 2022
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The correspondin ...
JUN 06, 2022
Drug Discovery & Development
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
JUN 06, 2022
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
Weight loss achieved via bariatric surgery among adults with obesity is linked to a lower risk of developing cancer and ...
Loading Comments...